Work

Abstract 4806: Exploring optimal targeted combination therapies with neratinib for HER2 mutated NSCLC

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2018-4806

Authors: Mari Kuraguchi, Luke J. Taus, Shan Zhou, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Paul Kirschmeier, Pasi A. Jänne

Institutions: Dana-Farber Cancer Institute, Puma Biotechnology (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2886430172

Cites:

Cited by:

Related to: 10